AmCham’s Pharmaceutical Committee has suggestions. Year after year, a key concern of the major pharmaceutical companies operating in Taiwan is the ease with which new drugs and new indications (meaning new applications for existing treatments) can enter the market. Given Taiwan’s single-payer universal healthcare system, much depends on whether the National Health Insurance Administration (NHIA)…